Automation of labelling of Lipiodol with high-activity generator-produced 188Re-Reference-Cited by-同舟云学术

Automation of labelling of Lipiodol with high-activity generator-produced 188Re

Published:2011-02 Issue:2 Volume:69 Page:426-430
ISSN:0969-8043
Container-title:Applied Radiation and Isotopes
language:en
Short-container-title:Applied Radiation and Isotopes

Author:

Lepareur Nicolas,Ardisson Valérie,Noiret Nicolas,Boucher Eveline,Raoul Jean-Luc,Clément Bruno,Garin Etienne

Funder

Région Bretagne

ARC

Ligue 35 and 56

Publisher

Elsevier BV

Subject

Radiation

Reference32 articles.

1. Radioembolization of liver tumors with yttrium-90 microspheres;Ahmadzadehfar;Semin. Nucl. Med.,2010

2. β-radiation exposure with 188Re-labelled radiopharmaceuticals;Andreeff;Nuklearmedizin,2005

3. International atomic energy agency—sponsored multination study of intra-arterial rhenium-188-labeled Lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study;Bernal;Semin. Nucl. Med.,2008

4. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors;Bilbao;Cardiovasc. Intervent. Radiol,2009

5. Primary liver cancer: world-wide incidence and trends;Bosch;Gastroenterology,2004

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 188Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study);Cancers;2023-04-11

2. Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry;Molecules;2023-02-03

3. Design and Preparation of Iodinated Brucea Javanica Oil as Dual Functional Anti-Tumor Agent for Treating Hepatocellular Carcinoma;Pharmaceutical Chemistry Journal;2022-09

4. Rhenium Radioisotopes for Medicine, a Focus on Production and Applications;Molecules;2022-08-18

5. Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy;Cancer Biotherapy and Radiopharmaceuticals;2022-02-01